A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension

Abroad (travel likely)RecruitingPHASE3

Conditions

Refractory Chronic Cough

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
Study leads
  • GSK Clinical Trials

    Study Director

    GlaxoSmithKline